{
    "clinical_study": {
        "@rank": "124220", 
        "arm_group": [
            {
                "arm_group_label": "ARM 1", 
                "arm_group_type": "Experimental", 
                "description": "Myeloablative"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "non-myeloablative"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "standard consolidation"
            }
        ], 
        "brief_summary": {
            "textblock": "We propose a phase II study to determine the impact of maintenance therapy with\n      5-azacytidine and GM-CSF in patients with poor-risk AML or MDS, who are in remission after\n      definitive treatment with either stem cell transplant or cytarabine-based consolidation\n      chemotherapy.\n\n      In order to precede relapse and to avoid lead time bias, treatment would need to commence\n      within 185 days of definitive therapy. Furthermore, approximately 50% of relapses occur\n      within the first year and up to 80% within two years after SCT, therefore we would limit the\n      duration of maintenance therapy to one year, followed by two years of follow-up."
        }, 
        "brief_title": "A Phase II Study of 5-Azacitidine and Sargramostim as Maintenance Treatment After Definitive Therapy for Poor-risk AML or MDS", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age >  6 months\n\n          2. Initial diagnosis of poor -risk AML or MDS (defined in section 3.2), treated with\n             either stem cell transplant or cytarabine-based consolidation chemotherapy, within\n             the past 60-185 days\n\n          3. ECOG performance status 0-2\n\n          4. No morphologic evidence of leukemia or active MDS as determined by  JHH\n             Hematopathologist independent review of a bone marrow aspirate and biopsy done\n             following the completion of therapy and within 14 days prior to enrollment\n\n          5. Peripheral blood count recovery: Neutrophil count \u2265 1000 /\u00b5L, platelet count \u2265 50x\n             109 /\u00b5L without platelet transfusions, and adequate hematocrit independent of red\n             cell transfusions .\n\n          6. No evidence of extramedullary leukemia, such as CNS or soft tissue involvement\n\n          7. Adequate end organ function as measured by the following:   AST and ALT < 4 x normal,\n             total serum bilirubin < 2 x upper limit normal (unless due to hemolysis, Gilbert's\n             syndrome, or ineffective erythropoiesis), creatinine < 2 x upper limit of normal\n\n          8. Ability to give informed consent\n\n          9. In agreement to use an effective barrier method of birth control to avoid pregnancy\n             during the study and for a minimum of 30 days after study treatment, for all male and\n             female patients who are fertile\n\n        Exclusion Criteria:\n\n          1. Patients with untreated or uncontrolled infections\n\n          2. Patients with untreated or uncontrolled grade 3 or 4 GVHD\n\n          3. Pregnancy and lactation\n\n          4. Concurrent use of any other investigational agents.\n\n          5. Known HIV-positive patients.\n\n          6. Known hypersensitivity to 5AC or GM-CSF"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700673", 
            "org_study_id": "J1240", 
            "secondary_id": [
                "P01CA015396", 
                "NA_00072223"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "ARM 1", 
                "Arm 2", 
                "Arm 3"
            ], 
            "description": "5-azacitidine will be administered days 1-5 of a 28 day cycle. sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.", 
            "intervention_name": "5-azacitidine and sargramostim", 
            "intervention_type": "Drug", 
            "other_name": "Vidaza, GM-CSF"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Cytarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "maintenance treatment", 
            "stem cell transplant", 
            "cytarabine-based chemotherapy"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
            }, 
            "investigator": {
                "last_name": "Margaret Showel, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Study of 5-Azacitidine (5AC) in Combination With Sargramostim (GM-CSF) as Maintenance Treatment, After Definitive Therapy With Either Stem Cell Transplant (SCT) or Cytarabine-based Chemotherapy, in Patients With Poor-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", 
        "overall_contact": {
            "last_name": "Margaret Showel, MD", 
            "phone": "410-614-7059"
        }, 
        "overall_contact_backup": {
            "email": "ntucker5@jhmi.edu", 
            "last_name": "Noah Tucker", 
            "phone": "410-614-7833"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "to evaluate the two-year relapse-free survival (RFS) of patients with poor-risk Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS), who receive maintenance treatment with 5-Azacytidine(5AC) in combination with GM-CSF during remission, following definitive therapy with either a stem cell transplant (SCT) or cytarabine-based consolidation chemotherapy.", 
            "measure": "To evaluate the 2 year relapse free survival of patients", 
            "safety_issue": "No", 
            "time_frame": "2 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700673"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "1.\tDescribe and quantify the toxicity profile of the combination of 5AC and GM-CSF", 
                "measure": "1. Describe and quantify the toxicity profile of the combination of 5AC and GM-CSF", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "2.\tDetermine the impact on one-year RFS and overall survival for poor-risk myeloid disorders following maintenance therapy with 5AC and GM-CSF", 
                "measure": "2. Determine the impact on one-year RFS and overall survival for poor-risk myeloid disorders following maintenance therapy with 5AC and GM-CSF", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}